ADVERTISEMENT

Not So Super

Will antibody therapies receive added scrutiny?
THIS IS A PREVIEW.
or subscribe to access the full article.

The drug's inventors called their creation a "superantibody." They hoped that it would be capable of activating immune cells other antibody drugs could not on their own. The moniker for the compound, targeted at autoimmune disease or leukemia, was TGN1412, made by TeGenero, based in W¿rzburg, Germany. On March 13 six previously healthy volunteers given the antibody in a routine test of its safety were sent to intensive care.

Although all the men are out of critical condition, one patient who went into a three-week coma after taking the drug may lose bits of his fingers and toes. Several medical experts assert that these results, which came after experiments with TGN1412 on rabbits and monkeys at up to 500 times the human dose, highlight the need for caution in designing trials of biotechnology drugs that work through novel mechanisms.

THIS IS A PREVIEW.
or subscribe to access the full article.
Buy Digital Issue $7.99
Print + Digital
All Access
$99.99 Subscribe
Rights & Permissions
Share this Article:

Comments

You must sign in or register as a ScientificAmerican.com member to submit a comment.

The perfect movie companion to
Jurassic World

Add promo-code: Jurassic
to your cart and get this digital issue for just $7.99!

Hurry this sale ends soon >

X

Email this Article

X